Breaking News

Alcobra Selects Premier Research for ADHD Study

Will conduct Phase III study of MG01CI in ADHD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alcobra Ltd. has selected Premier Research as its CRO to conduct a Phase III study of MG01CI as a potential treatment for adults with Attention Deficit Hyperactivity Disorder (ADHD).   “We are delighted to partner with Premier Research as we embark upon our most important clinical study to date. Premier Research has extensive knowledge and expertise regarding central nervous system (CNS) clinical trials, having conducted more than 150 CNS studies over the past five years, including numerou...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters